Positive mt-sDNA Testing Successfully Identifies Higher Number Of Advanced Serrated Lesions Than SBTs, Study Finds

Gastroenterology Advisor (8/27, Khaja) reports, “While stool-based tests (SBTs) do not show a significant difference in detecting advanced neoplasia, positive multitargeted stool DNA (mt-sDNA) testing successfully identifies a notably higher number of advanced serrated lesions, according to study results.” Researchers found that “the highest positive predictive value for advanced neoplasia was observed with mt-sDNA at 30.7%, followed by” fecal immunochemical tests at 22.8% and fecal occult blood tests at 18.8%. The findings were published in the Journal of Clinical Gastroenterology.